
VTVT
vTv Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
17.000
Open
17.000
VWAP
15.61
Vol
2.18K
Mkt Cap
49.64M
Low
15.520
Amount
34.05K
EV/EBITDA(TTM)
--
Total Shares
2.43M
EV
24.32M
EV/OCF(TTM)
--
P/S(TTM)
5.73K
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Show More
2 Analyst Rating

128.44% Upside
Wall Street analysts forecast VTVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTVT is 35.50 USD with a low forecast of 35.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy

128.44% Upside
Current: 15.540

Low
35.00
Averages
35.50
High
36.00

128.44% Upside
Current: 15.540

Low
35.00
Averages
35.50
High
36.00
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Initiates
$36
2025-04-09
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$36
2025-04-09
Initiates
Strong Buy
Reason
Alliance Global Partners
James Molloy
Strong Buy
Initiates
$35
2024-12-09
Reason
Alliance Global Partners
James Molloy
Price Target
$35
2024-12-09
Initiates
Strong Buy
Reason
Alliance Global Partners analyst James Molloy initiated coverage of vTv Therapeutics with a Buy rating and $35 price target. vTv is a clinical-stage pharmaceutical company focused on developing treatment options for metabolic and inflammatory diseases, primarily targeting type 1 diabetes, the analyst tells investors in a research note. The firm says cadisegliatin's mechanism of action allows for liver function restoration.
See All Ratings
Valuation Metrics
The current forward P/E ratio for vTv Therapeutics Inc (VTVT.O) is -4.58, compared to its 5-year average forward P/E of -3.21. For a more detailed relative valuation and DCF analysis to assess vTv Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.21
Current PE
-4.58
Overvalued PE
0.26
Undervalued PE
-6.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.27
Undervalued EV/EBITDA
-0.76
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
32.69
Current PS
0.00
Overvalued PS
74.65
Undervalued PS
-9.27
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+15.57%
-6.50M
Operating Profit
FY2025Q1
YoY :
+3.29%
-6.22M
Net Income after Tax
FY2025Q1
YoY :
-34.19%
-0.77
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
83.8K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
83.8K
USD
Months
0-12
0
0.0
USD
Months
VTVT News & Events
Events Timeline
2025-05-19 (ET)
2025-05-19
09:07:14
vTv Therapeutics appoints Tung as CFO

2025-05-15 (ET)
2025-05-15
16:08:13
vTv Therapeutics reports Q1 EPS (77c), consensus (81c)

2025-05-15
12:01:50
vTv Therapeutics reports reinitiation of screening in CATT1 Phase 3 trial

Sign Up For More Events
Sign Up For More Events
News
1.0
06-11NewsfiltervTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series
5.0
05-19NewsfiltervTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
4.0
04-09BenzingaThis Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Sign Up For More News
People Also Watch

CALC
CalciMedica Inc
3.800
USD
+2.98%

INTS
Intensity Therapeutics Inc
0.325
USD
0.00%

ARBK
Argo Blockchain PLC
0.343
USD
-9.97%

OM
Outset Medical Inc
18.530
USD
+5.22%

DMYY
DMY Squared Technology Group Inc
12.550
USD
-2.56%

ESHA
ESH Acquisition Corp
11.110
USD
-0.99%

PXS
Pyxis Tankers Inc
2.950
USD
-3.28%

ELEV
Elevation Oncology Inc
0
USD
-2.19%

BRNS
Barinthus Biotherapeutics PLC
1.790
USD
+2.58%

RAPT
RAPT Therapeutics Inc
13.310
USD
+5.22%
FAQ

What is vTv Therapeutics Inc (VTVT) stock price today?
The current price of VTVT is 15.54 USD — it has decreased -0.19 % in the last trading day.

What is vTv Therapeutics Inc (VTVT)'s business?

What is the price predicton of VTVT Stock?

What is vTv Therapeutics Inc (VTVT)'s revenue for the last quarter?

What is vTv Therapeutics Inc (VTVT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for vTv Therapeutics Inc (VTVT)'s fundamentals?

How many employees does vTv Therapeutics Inc (VTVT). have?
